DRRX

POSIMIR®(bupivacaine extended-release solution)

Post Operative Pain

Stage (next event)

Expected Date

NDA Acceptance

TBD

Catalyst Info & Data Links

TITLE: POSIMIR®(bupivacaine extended-release solution) for Post Operative Pain - NDA Acceptance

  • ClinicalTrials.gov (NCT02574520): Trial of Extended Release Bupivacaine for Pain Relief After Surgery (PERSIST)


WHAT IS THE NEXT CATALYST EVENT?

  • NDA Acceptance 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD (Latest Quarterly Call says its under review) 


PRIOR DATA

PRESS RELEASES

POSTERS



Mechanism of Action

MECHANISM OF ACTION

  • POSIMIR is the Company's investigational post-operative pain relief depot product that utilizes DURECT's patented SABER® technology. POSIMIR is designed to be administered directly into the surgical site to deliver bupivacaine for up to three days after surgery.

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon